EXACT Therapeutics

EXTX

NO0010852213

Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 03:36:07 2024-04-25 am EDT			5-day change	1st Jan Change
6.8 ^NOK	-2.86%		-2.86%	-43.33%

Apr. 19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

EXACT Therapeutics : Notice of Annual General Meeting 2021

May 25, 2021 at 04:14 pm EDT

25 May 2021 - The Annual General Meeting of EXACT Therapeutics AS ('EXACT-Tx' or
the 'Company') will be held on 1 June 2021 at 1300hrs CET. Please find attached
the notice of Annual General Meeting with attendance/Proxy, including the Board
of Directors' proposed resolutions for the items listed on the agenda. The
documents are also available at www.exact-tx.com
 
Due to the COVID-19 situation the Company's office is closed and the Annual
General Meeting will be held by proxy or by submitting votes in advance.
Shareholders who notify the company will be invited to participate in a
Microsoft Teams meeting, but votes need to be cast in advance. The deadline for
receiving proxies or votes is 30 May 2021 at 12:00 CET. The Annual General
Meeting will be efficiently carried through by strictly keeping to the agenda
items. 
 
For further information, please contact: Masha Stromme, Chair of the Board +47
930 22 509, masha_stromme@fastmail.fm
 
About EXACT Therapeutics AS: EXACT-Tx is a clinical stage Norwegian biotech
company developing a technology platform for targeted therapeutic enhancement -
Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to
ultrasound-mediated, targeted drug enhancement - with the potential to
significantly amplify the clinical utility of a wide range of therapeutic agents
across a multitude of indications including within oncology (chemotherapy,
immunotherapy), infectious diseases, and neurological conditions.
www.exact-tx.com

Click here for more information

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	23-10-31	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	23-09-27	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	23-09-26	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	23-09-25	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	23-09-06	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	23-09-05	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	23-08-07	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	23-08-06	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	23-07-31	CI
EXACT Therapeutics AS Announces Management Changes	23-06-09	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	23-03-27	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	23-02-02	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	23-02-02	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22-12-22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22-12-22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22-11-22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-21	CI
EXACT Therapeutics Appoints Chief Medical Officer	22-09-16	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	22-09-15	CI
Norway's Exact Therapeutics Appoints New CFO	22-08-31	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	22-08-30	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	22-06-23	MT

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-43.33%	20.42M
IQVIA HOLDINGS INC.	+1.61%	43.84B
MODERNA, INC.	+6.04%	41.68B
LONZA GROUP AG	+45.04%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.41%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.43%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.28%	12.29B
MEDPACE HOLDINGS, INC.	+26.58%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.79%	11.15B